NYSEAMERICAN:LCTX

Lineage Cell Therapeutics Stock Forecast, Price & News

$2.55

+0.13 (+5.37 %)

(As of 09/17/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.34

▼

$2.58

50-Day Range

$1.43

▼

$1.93

52-Week Range

$0.86

▼

$3.13

Volume5.32 million shs

Average Volume1.41 million shs

Market Capitalization$427.02 million

P/E RatioN/A

Dividend YieldN/A

Beta1.84

30 days | 90 days | 365 days | Advanced Chart

Receive LCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Ca

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives "Buy" Rating from HC Wainwright
September 16, 2021 | americanbankingnews.com

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from Noble Financial
September 16, 2021 | americanbankingnews.com

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
September 15, 2021 | finance.yahoo.com

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
September 13, 2021 | finance.yahoo.com

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Given Average Recommendation of "Buy" by Analysts
September 2, 2021 | americanbankingnews.com

Lineage Announces Appointment of General Counsel
September 1, 2021 | finance.yahoo.com

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript
August 13, 2021 | finance.yahoo.com

Lineage Cell (LCTX) Reports Q2 Loss, Misses Revenue Estimates
August 12, 2021 | finance.yahoo.com

Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
August 12, 2021 | finance.yahoo.com

Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
August 11, 2021 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:LCTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.lineagecell.com
Phone(510) 521-3390
Employees52
Year FoundedN/A

Sales & Book Value

Annual Sales$1.83 million
Price / Sales233.35
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.63 per share
Price / Book4.05

Profitability

EPS (Most Recent Fiscal Year)($0.13)
Net Income$-20,650,000.00
Net Margins-652.38%
Return on Equity-17.20%
Return on Assets-15.44%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares167,460,000
Market Cap$427.02 million
Next Earnings Date11/3/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.37 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Lineage Cell Therapeutics has a forecasted upside of 135.3% from its current price of $2.55.
Amount of Analyst Coverage
Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Lineage Cell Therapeutics has received 40 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Lineage Cell Therapeutics has received 13 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Lineage Cell Therapeutics has received 75.47% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Lineage Cell Therapeutics and other stocks. Vote “Outperform” if you believe LCTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LCTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Lineage Cell Therapeutics does not currently pay a dividend.
Dividend Growth
Lineage Cell Therapeutics does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lineage Cell Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,018.00 in company stock.
Percentage Held by Insiders
26.20% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.62% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Lineage Cell Therapeutics are expected to decrease in the coming year, from ($0.21) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lineage Cell Therapeutics is -31.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lineage Cell Therapeutics is -31.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lineage Cell Therapeutics has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Frequently Asked Questions

Is Lineage Cell Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lineage Cell Therapeutics stock.
View analyst ratings for Lineage Cell Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Lineage Cell Therapeutics?

Wall Street analysts have given Lineage Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lineage Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lineage Cell Therapeutics' next earnings date?

Lineage Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Lineage Cell Therapeutics.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.03). The firm earned $0.51 million during the quarter, compared to the consensus estimate of $1.05 million. Lineage Cell Therapeutics had a negative net margin of 652.38% and a negative trailing twelve-month return on equity of 17.20%.
View Lineage Cell Therapeutics' earnings history.

What price target have analysts set for LCTX?

6 brokers have issued 1-year price targets for Lineage Cell Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they expect Lineage Cell Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Lineage Cell Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Lineage Cell Therapeutics' key executives?

Lineage Cell Therapeutics' management team includes the following people:

Brian M. Culley, President, Chief Executive Officer & Director
Kevin L. Cook, Chief Financial & Accounting Officer
Gary S. Hogge, Senior Vice President-Clinical & Medical Affairs
François Binette, Global Head-Research & Development
Derek Kelaita, Vice President-Business Development

Who are some of Lineage Cell Therapeutics' key competitors?

Some companies that are related to Lineage Cell Therapeutics include Century Therapeutics (IPSC), Ocugen (OCGN), AlloVir (ALVR), Replimune Group (REPL), Immunocore (IMCR), Monte Rosa Therapeutics (GLUE), Inhibrx (INBX), Scholar Rock (SRRK), Sangamo Therapeutics (SGMO), Vaxcyte (PCVX), Valneva (VALN), Agenus (AGEN), Atara Biotherapeutics (ATRA), Icosavax (ICVX) and Krystal Biotech (KRYS).
View all of LCTX's competitors.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."

Who are Lineage Cell Therapeutics' major shareholders?

Lineage Cell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.11%), Vanguard Group Inc. (3.83%), Defender Capital LLC. (3.11%), Geode Capital Management LLC (1.40%), JPMorgan Chase & Co. (1.17%) and State Street Corp (1.12%). Company insiders that own Lineage Cell Therapeutics stock include Angus C Russell and Brian M Culley.
View institutional ownership trends for Lineage Cell Therapeutics.

Which institutional investors are selling Lineage Cell Therapeutics stock?

LCTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Creative Planning, Bridgeway Capital Management LLC, Susquehanna International Group LLP, Wealth Architects LLC, and Bank of America Corp DE. Company insiders that have sold Lineage Cell Therapeutics company stock in the last year include Angus C Russell, and Brian M Culley.
View insider buying and selling activity for Lineage Cell Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Lineage Cell Therapeutics stock?

LCTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., DekaBank Deutsche Girozentrale, and Nuveen Asset Management LLC.
View insider buying and selling activity for Lineage Cell Therapeutics or or view top insider-buying stocks.

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lineage Cell Therapeutics' stock price today?

One share of LCTX stock can currently be purchased for approximately $2.55.

How much money does Lineage Cell Therapeutics make?

Lineage Cell Therapeutics has a market capitalization of $427.02 million and generates $1.83 million in revenue each year. The company earns $-20,650,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics employs 52 workers across the globe.

What is Lineage Cell Therapeutics' official website?

The official website for Lineage Cell Therapeutics is www.lineagecell.com.

Where are Lineage Cell Therapeutics' headquarters?

Lineage Cell Therapeutics is headquartered at 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008.

How can I contact Lineage Cell Therapeutics?

Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company can be reached via phone at (510) 521-3390 or via email at [email protected].

This page was last updated on 9/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here